Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹® ¿¹Ãø(2025-2030³â)
Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Drug Class (Second- generation Antipsychotics, Third-Generation Antipsychotics), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1750781
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,191,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,568,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,321,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é ¼¼°èÀÇ Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 112¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2030³â ¿¬Æò±Õ 5.6%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù.

Á¶Çöº´ ½ÃÀåÀº ¾à¹°Àü´Þ ±â¼úÀÇ ¹ßÀü, Áö¼ÓÇü ÁÖ»çÁ¦(LAI)ÀÇ °¡¿ë¼º, Ä¡·á¸¦ ¿øÇϴ ȯÀÚ Áõ°¡ µîÀ¸·Î ÀÎÇØ Àü¹ÝÀûÀ¸·Î °ßÀ뵃 °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. »õ·Î¿î ¾à¹°ÀÇ º¸±ÞÀ» ÃËÁøÇÏ´Â ÁÖ¿ä Æ¯Â¡Àº ºü¸¥ ¾àÈ¿ ¹ßÇö, ȯÀÚ Á¢±Ù¼º, È¿À²¼º, ³ôÀº ȯÀÚ ¼øÀÀµµ µîÀÌ ²ÅÈ÷°í ÀÖ½À´Ï´Ù.

Á¶Çöº´Àº ȯÀÚ¿Í °¡Á·, »çȸ Àüü¿¡ Å« ºÎ´ãÀ» ÁÖ°í ÀÖ½À´Ï´Ù. Á¤½ÅÁúȯ, ƯÈ÷ Á¤½ÅºÐ¿­Áõ¿¡ ´ëÇÑ È¯ÀÚ¿Í ÀÇ»çÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó ½Å¾à ½ÃÀå ħÅõ¸¦ ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÇöÀç 2¼¼´ë¿Í 3¼¼´ë Ç×Á¤½Åº´Á¦¹°ÀÌ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇè ÁßÀÎ ÆÄÀÌÇÁ¶óÀÎ ÀǾàǰÀº ¼¼·ÎÅä´Ñ ¼ö¿ëü¿Í µµÆÄ¹Î ¼ö¿ëüÀÇ Æ¯Á¤ ¾ÆÇüÀ» Â÷´ÜÇÏ¿© Áõ»óÀ» ÃÖ¼ÒÈ­Çϰí, µµÆÄ¹Î ¼öÄ¡ »ó½ÂÀ» Á¶ÀýÇϸç, ±â¾ï·ÂÀ» Çâ»ó½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.

Á¶Çöº´ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î Intra-Cellular TherapiesÀÇ ITI-007, AlkermesÀÇ ALKS-3831°ú °°Àº À½¼º Áõ»ó Ä¡·á¸¦ À§ÇÑ ÈÄ±â ´Ü°è ÆÄÀÌÇÁ¶óÀÎ Á¦Ç°ÀÇ µîÀå¿¡ ÀÇÇØ ÁÖµµµÉ °ÍÀ¸·Î ¿¹»óµÇÁö¸¸, Á¶Çöº´ Ä¡·á ¿µ¿ª¿¡´Â Å« ¹ÌÃæÁ· ¼ö¿ä°¡ Á¸ÀçÇÕ´Ï´Ù. ¹ÌÃæÁ· ¼ö¿ä°¡ Á¸ÀçÇÕ´Ï´Ù. ±×·¯³ª Á¶Çöº´ Ä¡·á ºÐ¾ß¿¡´Â Å« ¹ÌÃæÁ· ¼ö¿ä°¡ Á¸ÀçÇÕ´Ï´Ù. Á¤È®ÇÑ Áúº´ ¸ÞÄ¿´ÏÁò¿¡ ´ëÇÑ ÀÌÇØ°¡ ºÎÁ·ÇÏ¿© ȹ±âÀûÀÎ Ä¡·áÁ¦ÀÇ ¹ß°ßÀ» °¡·Î¸·°í ÀÖ´Â °ÍÀÔ´Ï´Ù. µû¶ó¼­ ÀÌ ¼è¾àÇØÁö´Â Áúº´À» Ä¡·áÇϱâ À§Çؼ­´Â ¾à¹°Àü´Þ ±â¼úÀÇ Çõ½ÅÀÌ ÇÊ¿äÇÕ´Ï´Ù.

Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå : ¾àÁ¦ Ŭ·¡½º ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå : Åõ¿© °æ·Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå : À¯Åë ä³Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå Á¶Çöº´ Ä¡·áÁ¦ ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®, ¾àÁ¦ Ŭ·¡½ºº°, À¯Åë ä³Îº°, Åõ¿© °æ·Îº°

Á¦8Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.6% from 2025 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Schizophrenia Drugs Market Variables, Trends & Scope

Chapter 4. Schizophrenia Drugs Market: Drug Class Estimates & Trend Analysis

Chapter 5. Schizophrenia Drugs Market: Route of Administration Estimates & Trend Analysis

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Distribution Channel, and Route of Administration

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â